Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
This study was conducted to evaluate the response rate of gemcitabine and cisplatin as second-line combination chemotherapy in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Thirty-eight eligible women with measurable disease and anthracycline- and taxane-pretreated MBC were enrolled. The chemotherapy treatment consisted of gemcitabine (1,250 mg/m(2) by intravenous infusion over 30 min on days 1 and 8) and cisplatin (75 mg/m(2) by intravenous infusion over 1 h on day 1), which were administered every 21 days. Thirty-seven of 38 (97.4%) of patients were assessable for response. The objective response rate was 42.1% (95% CI, 26.4-57.8%) with 16 partial responses. The median time to progression (TTP) and overall survival (OS) for all patients were 5.4 months (95% CI, 2.7-8.1 months) and 13.9 months (95% CI, 9.4-18.4 months), respectively. The most frequent hematologic-related adverse events were grade 3/4 leucopenia and thrombocytopenia, observed in 10 patients (27.0%) and 11 (29.7%), respectively. Grade 3 stomatitis was observed in 3 (8.1%) patients. No grade 4 nonhematologic toxicity was observed in this study. No treatment-related deaths occurred during the study. In conclusion, the combination of gemcitabine and cisplatin is a safe and tolerable regimen as second-line combination for patients with anthracycline- and taxane-pretreated MBC.
Department of Breast Cancer, Hospital Affiliated to Academy Military Medical Science, No 8, Dong Street, 100071 Fengtai District, Beijing, People's Republic of China.
Tao
T
Wang
Shaohua
S
Zhang
Min
M
Zeng
Xinyou
X
Lu
Ge
G
Shen
Shikai
S
Wu
Santai
S
Song
Zefei
Z
Jiang
D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D016879:Salvage Therapy / Q000379:methods*; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome; D000093542:Gemcitabine
D018943:Anthracyclines; D043823:Taxoids; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine
Control Clin Trials. 1989 Mar;10(1):1-10
2702835
Cancer Res Treat. 2008 Sep;40(3):101-5
19688114
Ann Oncol. 1999 Apr;10(4):441-8
10370787
J Clin Oncol. 2006 May 10;24(14):2137-50
16682732
Cancer Chemother Pharmacol. 2007 Feb;59(2):269-74
16763791
J Egypt Natl Canc Inst. 2004 Mar;16(1):8-14
15716992
Clin Cancer Res. 1996 Mar;2(3):521-30
9816199
Oncology. 2001;60(4):303-7
11408796
J Clin Oncol. 1995 Nov;13(11):2731-6
7595731
J Biol Chem. 1998 Aug 21;273(34):21482-8
9705276
Oncology. 2008;75(3-4):175-81
18841031
Cancer Chemother Pharmacol. 2006 May;57(5):640-6
16163537
Clin Transl Oncol. 2007 Jul;9(7):459-64
17652060
Chemotherapy. 2009;55(3):155-60
19390188
Am J Clin Oncol. 2005 Apr;28(2):195-200
15803016
J Clin Oncol. 2000 Jun;18(11):2245-9
10829044
Oncology. 2002;62(1):2-8
11810037
J Clin Oncol. 2003 Mar 15;21(6):959-62
12637456
Oncology. 2001;60(1):60-5
11150910
J Clin Oncol. 1995 Dec;13(12):2879-85
8523050
J Clin Oncol. 2009 May 1;27(13):2163-9
19307510
Oncologist. 2001;6 Suppl 3:17-21
11346680
Breast J. 2010 May-Jun;16(3):252-63
20408828